Full-Time

Field Medical Outcomes Therapeutic Area Lead Senior Director

Posted on 9/10/2026

Deadline 9/21/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$214.9k - $358.1k/yr

+ 22.5% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Remote in USA + 1 more

More locations: New York, NY, USA

Hybrid

Travel up to 30% is required, including overnight travel; relocation assistance may be available based on eligibility.

Bachelor's, PharmD, PhD

Category
Biology & Biotech
Required Skills
Market Research
Electronic Health Records (EHR)
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A terminal doctorate degree, specifically PharmD or PhD.
  • At least 7 years of relevant experience, including significant experience in clinical patient care, formulary management, medical account management, pharmacoeconomic and outcomes research, and strong methodological skills in study design, data analysis, and interpretation.
  • Experience in at least 3 of the following 5 areas: leading a matrix organization without direct authority; pharmaceutical industry experience; healthcare quality improvement project experience; people management in a healthcare environment; or data analytics, pharmacoeconomic and outcomes research with strong methodological skills in health services research.
  • Ability to influence and collaborate with peers and create business impact.
  • Strong oral and written communication skills.
  • Strong analytic skills, including proactively identifying and addressing challenges.
  • Experience analyzing healthcare data, including real-world evidence, claims, electronic health records, and other healthcare data.
  • Ability to communicate large amounts of scientific information clearly and concisely.
  • Ability to organize work, prioritize multiple demands, remain flexible, and use situational leadership skills.
  • Ability to understand and respond to multiple external and internal customers' demands and handle conflict constructively.
  • Ability to manage and implement multiple projects in a remote environment while prioritizing effectively and exercising sound judgment.
  • Ability to work within a matrixed, multidisciplinary team and foster professional relationships aligned with medical objectives.
  • Ability to lead change in an evolving external healthcare environment.
  • Ability to adapt to new therapeutic areas and organizational change.
  • Ability to problem-solve and network across the enterprise to identify solutions.
  • Ability to collaborate effectively and demonstrate leadership and teamwork with peers, internal stakeholders, and external customers.
  • Ability to be accountable and deliver results that create medical impact and a positive customer experience.
  • Ability to maintain self-awareness and choose behaviors that support performance and engagement.
  • Clinical and technical skills, including the ability to adopt and use new digital technology and record medical interactions.
  • Authorization to be employed in the United States by any employer.
  • Permanent work authorization in the United States.
Responsibilities
  • Maintain product and disease-area competency to collaborate effectively with medical and commercial colleagues and external customers and key opinion leaders.
  • Share customer insights with leadership to guide strategy and tactic development.
  • Develop FMO strategic and tactical plans with medical advisory, payer health trends and channel, headquarters medical affairs, global real-world evidence and epidemiology, and health value and evidence colleagues.
  • Conduct annual SWOT analysis, identify strategies and tactics, and develop budgets for high-priority FMO issues and opportunities.
  • Establish annual FMO therapeutic-area medical objectives and activity and impact goals with FMO leadership.
  • Lead execution of FMO strategic and tactical plans with FMO leadership, medical advisory teams, headquarters medical leads, and real-world evidence and health value and evidence leads.
  • Incorporate customer insights into strategic and tactical planning.
  • Conduct advisory boards and qualitative research, including participant recruitment, discussion-guide development, consultant contract development, and final reports with recommendations.
  • Develop medical affairs agency statements of work, provide review and feedback, and manage budgets and quarterly forecasts for finance.
  • Coordinate permissions and copyrights for FMO resource development.
  • Prepare submissions for FMO tactics to brand, medical, and U.S. Market Access customer marketing review committees.
  • Attend meetings where FMO materials are reviewed.
  • Coordinate incorporation of review comments into final tactics.
  • Manage back-end processes for producing and warehousing print-based FMO materials when needed.
  • Upload resources and usage guidelines to the CRC site and PROMOS for field medical access.
  • Ensure FMO colleagues are trained on resources.
  • Monitor expiration dates on FMO therapeutic-area resources and update them as appropriate.
  • Assess resource use with FMO medical advisory teams before renewal or updating.
  • Assess performance against the FMO therapeutic-area plan monthly with FMO medical advisory teams.
  • Collaborate with headquarters therapeutic-area medical affairs and field-based medical teams to develop strategies and tactics supporting product access, patient-care quality, and medication adherence.
  • Support development of FMO resources for pipeline, new-product, and new-indication launches.
  • Participate in headquarters medical affairs publications and annual consultant-needs planning.
  • Participate in therapeutic-area integrated evidence plan development to include concepts supporting FMO medical objectives.
  • Engage medical advisory and payer health trends and channel subteams to assess execution progress and course corrections.
  • Support national and regional FMO teams in customer engagement opportunities.
  • Lead dissemination and execution of product FMO strategy with field-based medical teams.
  • Participate with real-world evidence and health value and evidence teams in abstracts, posters, presentations, and publications.
  • Participate in headquarters planning with commercial marketing and sales leads to align goals.
  • Review payer, health professional, and consumer market research and incorporate relevant insights into medical strategy and customer initiatives.
  • Contribute to customer strategic planning with FMO, payer channel access leadership, and account management.
  • Provide strategic medical insight for National Account operating plans aligned with Pfizer operating imperatives.
  • Meet regularly with payer channel access leadership and national and regional account leads.
  • Engage external opinion leaders for advisory boards and medical affairs webinars.
  • Engage external opinion leaders in developing FMO tactics.
  • Engage external partners for technology platforms supporting FMO tactics.
  • Engage medical affairs agency teams in developing FMO tactics.
  • Participate in customer meetings and initiatives with field-based FMO colleagues to advance access, quality of care, and medication adherence.
  • Identify key thought leaders through literature review and participation in conferences and conventions.
  • Participate in customer collaborations or research opportunities requiring headquarters support.
  • Develop strategic medical partnerships to improve patient outcomes.
  • Engage organizational and market stakeholders and influencers, including Quality Improvement Organizations, advocacy groups, coalitions, and medical and healthcare associations.
  • Enhance customer recognition through collaborative projects, publications, and healthcare awards.
  • Manage resources strategically.
  • Ensure compliance with policies and procedures for reporting activities, impacts, and unsolicited medical request entries.
  • Work within standard operating procedures and Corporate Integrity Agreement guidelines.
Desired Qualifications
  • Familiarity with internal and external standard operating procedures, rules, and regulations governing Pfizer and customer interactions and relationships.
  • Understanding of the complex U.S. healthcare business environment and emerging healthcare trends.
  • Previous field medical or outcomes experience, five years of Pfizer medical account management, or management experience in multiple capacities.
  • Experience applying health information technology in clinical, functional, and technical settings in the United States, including analysis of claims, electronic health records, and other healthcare data.
  • Leadership in innovative project start-up and management.
  • Graduation from a U.S.-accredited healthcare program.
  • Residency or fellowship.
  • Pharmacy degree.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose to $15 billion, and non-COVID products grew 5% operationally.
  • Pfizer raised 2026 guidance to $60.5 billion-$62.5 billion after Eliquis, Padcev, Vyndaqel strength.
  • Berobenatide entered Phase 3 planning, giving Pfizer a credible obesity franchise before 2028.

What critics are saying

  • Depo-Provera MDL exceeded 5,800 cases by July 2026, with late-2026 bellwethers looming.
  • Vyndamax still faces Apotex litigation in Delaware, preserving generic-entry uncertainty beyond 2031.
  • Ringaskiddy and Catania cuts show manufacturing contraction, signaling more restructuring through 2029.

What makes Pfizer unique

  • Seagen gives Pfizer leading ADCs: Padcev, Tivdak, Adcetris, Tucysa across oncology.
  • Pfizer still owns COMIRNATY distribution scale, with XFG vaccine approved August 27, 2026.
  • Vyndamax settlement extends U.S. exclusivity to June 1, 2031, stabilizing cardiomyopathy cash flows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.